Michael Hertl
#162,556
Most Influential Person Now
Researcher
Michael Hertl's AcademicInfluence.com Rankings
Michael Hertlcomputer-science Degrees
Computer Science
#9470
World Rank
#9944
Historical Rank
Computational Linguistics
#2290
World Rank
#2313
Historical Rank
Machine Learning
#4149
World Rank
#4198
Historical Rank
Artificial Intelligence
#4493
World Rank
#4555
Historical Rank
Download Badge
Computer Science
Michael Hertl's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is Michael Hertl Influential?
(Suggest an Edit or Addition)Michael Hertl's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. (2008) (465)
- A single cycle of rituximab for the treatment of severe pemphigus. (2007) (351)
- Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. (2012) (274)
- Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia (2007) (270)
- Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology (2015) (254)
- Pemphigus. S2 Guideline for diagnosis and treatment – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV) (2015) (224)
- Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. (1998) (211)
- Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview (2000) (197)
- Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. (2018) (197)
- Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response (2013) (194)
- Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. (2002) (191)
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) (2011) (189)
- Guidelines on the use of extracorporeal photopheresis (2013) (182)
- Infliximab in the treatment of moderate to severe atopic dermatitis. (2005) (181)
- T cell control in autoimmune bullous skin disorders. (2006) (178)
- Braun-Falco’s Dermatologie, Venerologie und Allergologie (2012) (178)
- Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. (2002) (176)
- Rituximab exerts a dual effect in pemphigus vulgaris. (2008) (172)
- Autoimmune bullous skin diseases. Part 1: Clinical manifestations (2011) (168)
- Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. (2007) (163)
- Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. (2008) (160)
- Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris1 (2004) (154)
- Recommendations for the use of rituximab (anti‐CD20 antibody) in the treatment of autoimmune bullous skin diseases § (2008) (148)
- Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface. (2012) (140)
- Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. (2011) (133)
- Autoimmune bullous skin diseases. Part 2: diagnosis and therapy (2011) (130)
- Pemphigus: Current and Future Therapeutic Strategies (2019) (129)
- Birch Pollen Immunotherapy Leads to Differential Induction of Regulatory T Cells and Delayed Helper T Cell Immune Deviation (2010) (127)
- Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. (2015) (125)
- Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. (1998) (124)
- Predominance of epidermal CD8+ T lymphocytes in bullous cutaneous reactions caused by beta-lactam antibiotics. (1993) (123)
- Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches (2018) (119)
- BP230- and BP180-specific auto-antibodies in bullous pemphigoid. (2004) (113)
- Lymphocyte activation in cutaneous drug reactions. (1995) (113)
- Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) (2020) (112)
- S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid (2015) (108)
- Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. (1998) (108)
- Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies. (2012) (107)
- Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles1 (2003) (106)
- Humoral and Cellular Autoimmunity in Autoimmune Bullous Skin Disorders (2000) (102)
- Autoreactive T and B Cells from Bullous Pemphigoid (BP) Patients Recognize Epitopes Clustered in Distinct Regions of BP180 and BP2301 (2006) (102)
- IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. (1999) (102)
- Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'? (2006) (101)
- IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis (2000) (101)
- S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid (2015) (97)
- Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus. (2018) (94)
- Selective generation of CD8+ T‐cell clones from the peripheral blood of patients with cutaneous reactions to beta‐lactam antibiotics (1993) (94)
- CD8+ dermal T cells from a sulphamethoxazole‐induced bullous exanthem proliferate in response to drug‐modified liver microsomes (1995) (93)
- Molecular Diagnosis in Autoimmune Skin Blistering Conditions (2014) (92)
- Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). (2001) (91)
- Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. (2007) (90)
- IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. (2011) (90)
- IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. (2000) (85)
- Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). (2007) (85)
- Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. (2012) (83)
- Severity score indexes for blistering diseases. (2012) (80)
- Rapid control of therapy‐refractory pemphigus vulgaris by treatment with the tumour necrosis factor‐α inhibitor infliximab (2005) (80)
- Canakinumab in adults with steroid‐refractory pyoderma gangrenosum (2015) (76)
- Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor‐α inhibitor, infliximab (2005) (75)
- Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor‐α inhibitor, infliximab (2005) (75)
- B-cell-directed therapy for inflammatory skin diseases. (2009) (73)
- Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan‐linked polyvinylalcohol adsorber (2003) (73)
- Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. (2009) (72)
- T Cell Recognition of Desmoglein 3 Peptides in Patients with Pemphigus Vulgaris and Healthy Individuals1 (2004) (72)
- Autoantibodies against desmocollins in European patients with pemphigus (2009) (71)
- Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult‐to‐treat pemphigus vulgaris (2012) (70)
- Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. (2010) (70)
- IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris (2001) (69)
- Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology (2016) (67)
- Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. (2005) (66)
- Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus (2016) (66)
- Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. (1998) (65)
- An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone (2017) (62)
- Targeted Therapies for Autoimmune Bullous Diseases: Current Status (2018) (61)
- TNF‐α: a treatment target or cause of sarcoidosis? (2015) (61)
- Prolonged Clinical Remission of Patients with Severe Pemphigus upon Rapid Removal of Desmoglein-Reactive Autoantibodies by Immunoadsorption (2006) (60)
- Inhibition of the Transcription Factor Foxp3 Converts Desmoglein 3-Specific Type 1 Regulatory T Cells into Th2-Like Cells1 (2006) (58)
- Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab (2008) (56)
- CHILD syndrome in 3 generations: the importance of mild or minimal skin lesions. (2006) (56)
- Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus (2019) (56)
- International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita (2018) (55)
- An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab (2015) (55)
- Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases (2007) (54)
- TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. (2018) (54)
- Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris (2013) (53)
- Immunoadsorption in pemphigus (2006) (53)
- Preferential Usage of TCR-Vβ17 by Peripheral and Cutaneous T Cells in Nickel-Induced Contact Dermatitis1 (2001) (53)
- IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses (2009) (53)
- IgG reactivity against non‐conformational NH2‐terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris (2006) (51)
- Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus (2016) (51)
- Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases (2012) (50)
- Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells (2014) (48)
- HLA class II restriction of autoreactive T cell responses in pemphigus vulgaris: review of the literature and potential applications for the development of a specific immunotherapy. (1999) (48)
- Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus (2017) (47)
- Characterization of T cell responses to fragrances. (2001) (47)
- Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin‐332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients (2011) (47)
- IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris (2007) (47)
- Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. (2019) (47)
- BP180‐ and BP230‐specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid? (2014) (46)
- Analysis of the T Cells that Are Potentially Involved in Autoantibody Production in Pemphigus Vulgaris (1999) (46)
- T-cell subsets in drug-induced toxic epidermal necrolysis. (1992) (46)
- Type I Regulatory T Cells in Autoimmunity and Inflammatory Diseases (2006) (44)
- [Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group]. (2005) (44)
- Autoimmune Diseases of the Skin (2001) (44)
- European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II (2021) (43)
- Frequency analysis of autoreactive T‐helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme‐linked immunospot assay (2000) (41)
- T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. (2003) (41)
- A systematic review with pooled analysis of clinical presentation and immunodiagnostic testing in mucous membrane pemphigoid: association of anti‐laminin‐332 IgG with oropharyngeal involvement and the usefulness of ELISA (2016) (40)
- Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study (2008) (39)
- Successful treatment of therapy‐resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody) (2004) (39)
- Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases (2011) (39)
- IgA autoantibodies in the pemphigoids and linear IgA bullous dermatosis (2010) (38)
- Autoimmune diseases of the skin : pathogenesis, diagnosis, management (2001) (38)
- IgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. (2012) (38)
- Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis (2017) (38)
- Pemphigus – Paradigm of Autoantibody-Mediated Autoimmunity (2001) (38)
- Pharmacological advances in pemphigoid. (2019) (37)
- Delayed response of oral pemphigus vulgaris to rituximab treatment. (2006) (36)
- European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology (2016) (36)
- A multi‐hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA‐DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading? (2017) (35)
- Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases (2012) (35)
- Allergic contact dermatitis from povidone‐iodine (1999) (34)
- Meeting Report of the Pathogenesis of Pemphigus and Pemphigoid Meeting in Munich, September 2016. (2017) (33)
- Immunologic mechanisms of cutaneous drug reactions. (1996) (33)
- T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita. (2010) (33)
- Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations. (2008) (33)
- S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update (2020) (33)
- The expanding spectrum of IgA pemphigus: a case report and review of the literature (2014) (31)
- Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis (2017) (31)
- Pemphigus vulgaris localized to the nose and cheeks. (2002) (30)
- Thymoma-Associated Paraneoplastic Autoimmune Multiorgan Syndrome—From Pemphigus to Lichenoid Dermatitis (2019) (30)
- Immunophenotyping in pemphigus reveals a Th17/Tfh17-dominated immune response promoting desmoglein1/3-specific autoantibody production. (2020) (30)
- Ex vivo analysis of desmoglein 1‐responsive T‐helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals (2005) (29)
- Flotillins Directly Interact with γ-Catenin and Regulate Epithelial Cell-Cell Adhesion (2013) (29)
- Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions. (2018) (29)
- Cellular and Humoral Mechanisms of Immune Tolerance in Immediate-Type Allergy Induced by Specific Immunotherapy (2008) (29)
- Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris (2010) (29)
- Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype (2010) (28)
- Efficacy of cyclophosphamide in toxic epidermal necrolysis. (1993) (28)
- Diagnostic value of an enzyme‐linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders (2003) (28)
- Results of a survey of German dermatologists on the therapeutic approaches to pemphigus and bullous pemphigoid (2009) (27)
- COVID‐19 and implications for dermatological and allergological diseases (2020) (27)
- Bullous cryothermic dermatitis artefacta induced by deodorant spray abuse (2011) (27)
- Deutliche Einschränkung der Lebensqualität bei Patienten mit Pemphigus vulgaris: Ergebnisse der deutschen Bullous Skin Disease (BSD)‐Studiengruppe (2005) (26)
- Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis (2020) (26)
- Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients (2018) (25)
- Photodynamic therapy in oral lichen planus: A prospective case-controlled pilot study (2020) (25)
- From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy. (2010) (25)
- The accessory function of B lymphocytes is resistant to the adverse effects of UV radiation (1991) (25)
- Neue Erkenntnisse zu Fumarsäureestern (Fumaderm®): Ergebnisse des 2. Experten‐Workshops (2011) (25)
- Comorbidities, metabolic risk profile and health‐related quality of life in German patients with plaque‐type psoriasis: a cross‐sectional prospective study (2013) (25)
- Loss of flotillin expression results in weakened desmosomal adhesion and Pemphigus vulgaris-like localisation of desmoglein-3 in human keratinocytes (2016) (25)
- European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I (2021) (25)
- Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects. (1995) (24)
- Autoimmune bullous disorders (2006) (24)
- European Guidelines (S1) on the use of high‐dose intravenous immunoglobulin in dermatology (2017) (24)
- Allergological approach to drug hypersensitivity reactions (2008) (24)
- B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid (2019) (23)
- Fumaric acid esters in severe ulcerative necrobiosis lipoidica: a case report and evaluation of current therapies. (2010) (23)
- Role of Src and Cortactin in Pemphigus Skin Blistering (2019) (22)
- Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease (2019) (22)
- Induction of T regulatory cells by the superagonistic anti‐CD28 antibody D665 leads to decreased pathogenic IgG autoantibodies against desmoglein 3 in a HLA‐transgenic mouse model of pemphigus vulgaris (2016) (22)
- Lymphocyte activation in allergic reactions elicited by small-molecular-weight compounds. (1997) (21)
- Differential IgG recognition of desmoglein 3 by paraneoplastic pemphigus and pemphigus vulgaris sera. (2012) (21)
- Treatment of inflammatory dermatoses by tumour necrosis factor antagonists (2006) (21)
- Brunsting-Perry Pemphigoid of the Scalp with Antibodies against Laminin 332 (2011) (20)
- The Drug Ambassador Project - The diversity of diagnostic procedures for drug allergy around Europe (2005) (20)
- Allelic and copy-number variations of FcγRs affect granulocyte function and susceptibility for autoimmune blistering diseases. (2015) (20)
- Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review (2020) (20)
- Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV) (2022) (20)
- Identification of Autoreactive B Cell Subpopulations in Peripheral Blood of Autoimmune Patients With Pemphigus Vulgaris (2019) (19)
- Repetitive Immunoadsorption Cycles for Treatment of Severe Atopic Dermatitis (2015) (19)
- BP 230-and BP 180-Specific AutoAntibodies in Bullous Pemphigoid (2004) (19)
- Retracted: Desmoglein 3‐specific T regulatory 1 cells consist of two subpopulations with differential expression of the transcription factor Foxp3 (2009) (18)
- Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases (2022) (18)
- Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers. (2007) (18)
- Overlap of IgA pemphigus and linear IgA dermatosis in a patient with ulcerative colitis: a mere coincidence? (2014) (17)
- Rituximab (Anti-CD20 Monoclonal Antibody) – Ultimate or First Choice in Pemphigus? (2007) (17)
- Melanoma‐associated chondroitin sulphate proteoglycan as a new target antigen for CD4+ T cells in melanoma patients (2009) (17)
- Use of high‐dose immunoglobulins in dermatology (2009) (16)
- S2k‐Leitlinie zur Diagnostik des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids (2015) (15)
- Metabolites and allergic drug reactions. (1998) (15)
- Proteome Dynamics in Biobanked Horse Peripheral Blood Derived Lymphocytes (PBL) with Induced Autoimmune Uveitis (2017) (15)
- Diagnosis of anti‐laminin γ‐1 pemphigoid by immunoblot analysis (2018) (14)
- Histamine Receptors on Lymphocytes: Distribution and Functional Significance (2000) (14)
- [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]. (2003) (13)
- Association with HLA-DRB1 in Egyptian and German pemphigus vulgaris patients. (2015) (13)
- IgG and IgA antibodies in linear IgA/IgG bullous dermatosis target the ectodomain of bullous pemphigoid antigen 2. (1999) (13)
- Blasenbildende Autoimmundermatosen. Teil 1: Klinik (2011) (13)
- Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus. (2008) (13)
- Infliximab in a patient with refractory mucosal aphthosis (2007) (12)
- Paraneoplastic pemphigus with anti‐BP180 autoantibodies and Castleman disease (2017) (12)
- Drug Metabolism and Drug Allergy (1991) (12)
- [Autoimmune bullous skin disorders]. (2010) (12)
- RITUXIMAB AND CORTICOSTEROID EFFECT ON DESMOGLEIN-SPECIFIC B-CELLS AND DESMOGLEIN-SPECIFIC T-FOLLICULAR-HELPER-CELLS IN PEMPHIGUS. (2021) (11)
- Contact dermatitis from clotrimazole with positive patch‐test reactions also to croconazole and itraconazole (1999) (11)
- Therapeutischer Einsatz der Tumor‐Nekrose‐Faktor‐α‐Hemmer Infliximab und Etanercept bei entzündlichen Hauterkrankungen (2003) (11)
- Rituximab for severe mucous membrane pemphigoid: safe enough to be drug of first choice? (2011) (11)
- S2k‐Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update (2020) (11)
- Autoimmune bullous skin disorders (2001) (10)
- S2k‐Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoid (2015) (10)
- Autoreactive T cells as potential targets for immunotherapy of autoimmune bullous skin diseases. (2001) (9)
- [Simultaneous onset of pemphigoid and factor VIII antibody hemophilia]. (2002) (9)
- Anaphylaxis caused by contact urticaria because of epoxy resins: an extraordinary emergency (2008) (9)
- In vitro lymphocyte responses to beta-lactam antibiotics in penicillin allergy : cross reactivity between penicillins and cephalosporins (1992) (9)
- Human desmocollin 3-specific IgG antibodies are pathogenic in a humanized HLA-class II transgenic mouse model of pemphigus. (2021) (9)
- The humanized SCID mouse model to study HLA class II‐linked autoimmunity to desmoglein 3 in pemphigus vulgaris (2002) (9)
- The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants (2020) (9)
- Underrecognition of the heterogeneous clinical spectrum of bullous pemphigoid. (2013) (8)
- Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders (2021) (8)
- [Bullous drug reactions]. (2005) (8)
- Interleukin 17 as a therapeutic target of acute generalized exanthematous pustulosis (AGEP). (2020) (8)
- Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel (2008) (8)
- Einsatz hochdosierter intravenöser Immunglobuline in der Dermatologie (2003) (8)
- Blasenbildende Autoimmundermatosen. Teil 2: Diagnostik und Therapie (2011) (7)
- [Bullous autoimmune dermatoses. 2: Pathogenesis]. (2002) (7)
- Contact dermatitis from levobunolol eyedrops (1999) (7)
- Childhood Pemphigus Foliaceus with Exclusive Immunoglobulin G Autoantibodies to Desmocollins (2016) (7)
- COVID‐19 und Auswirkungen auf dermatologische und allergologische Erkrankungen (2020) (7)
- A novel lateral flow immunoassay for the rapid detection of anti‐Dsg3 IgG serum autoantibodies in pemphigus vulgaris (2018) (7)
- [Bullous autoimmune dermatoses. 3: Diagnosis and therapy]. (2002) (7)
- Murine epidermal Langerhans Cells Do Not Express the Low-Affinity Receptor for Immunoglobulin E, FcεRII (CD23) (1996) (7)
- CD3-Positive B Cells: A Storage-Dependent Phenomenon (2014) (6)
- [The use of high dose intravenous immunoglobulins in dermatology]. (2003) (6)
- Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans (2021) (6)
- Bullöses Pemphigoid – Diagnostik und Therapie (2014) (6)
- Rowell syndrome with palmoplantar involvement and suspected epitope spreading. (2007) (6)
- [Molecular diagnosis of autoimmune dermatoses]. (2016) (6)
- Treatment of anti‐laminin γ1 pemphigoid with mycophenolate mofetil (2015) (6)
- Differential clinical response to alefacept in combination with methotrexate in two patients with refractory palmar psoriasis (2007) (6)
- Treating Autoimmune Bullous Skin Disorders with Biologics (2007) (6)
- Spättypreaktionen auf Heparine und Heparinoide : Hirudin als therapeutische Alternative : Eine Fallbeschreibung (1998) (6)
- Adjuvant high-dose intravenous immunoglobulins for recalcitrant erosive oral lichen planus: mixed clinical responses (2018) (5)
- [Chronic pruritus in autoimmune dermatoses : results of a comparative survey]. (2012) (5)
- Europäische Leitlinien (S1) für die Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie (2017) (5)
- A constant chromosome aberration in two children with acute myeloic leukaemia (1967) (5)
- Strukturen und Leistungsmerkmale der Hautkliniken in Deutschland: Aktuelle Bestandsaufnahme und Langzeitverlauf (2021) (5)
- Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC–MS/MS (2021) (5)
- Novel Therapeutic Approaches in Autoimmune Skin Disorders (2001) (5)
- [Diagnostic use of autoantibodies]. (2007) (5)
- Inpatient care for skin diseases in Germany: multi‐source analysis on the current and future health care needs (2021) (5)
- Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases. (2021) (4)
- From epidemiology and genetics to diagnostics, outcome measures, and novel treatments in autoimmune bullous diseases. (2014) (4)
- Therapeutic strategies for oral lichen planus: State of the art and new insights (2022) (4)
- Assessment of serious infections in pemphigus and pemphigoid by a national registry (2018) (4)
- Successful rituximab treatment of juvenile bullous pemphigoid with esophageal scarring due to epitope spreading (2016) (4)
- Amyopathic and anti-TIF1 gamma-positive dermatomyositis: analysis of a monocentric cohort and proposal to update diagnostic criteria (2020) (4)
- The controversy of hepatitis C and rituximab: A multidisciplinary dilemma with implications for patients with pemphigus (2016) (4)
- Subject Index Vol. 14, 2001 (2001) (4)
- [New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. (2012) (4)
- Subunit-Specific Reactivity of Autoantibodies Against Laminin-332 Reveals Direct Inflammatory Mechanisms on Keratinocytes (2021) (4)
- Murine epidermal Langerhans cells do not express the low-affinity receptor for immunoglobulin E, FcEpsilonRII (CD23). (1996) (4)
- Correction: Inhibition of the Transcription Factor Foxp3 Converts Desmoglein 3-Specific Type 1 Regulatory T Cells into Th2-Like Cells (2012) (3)
- Generation of increased numbers of HLA-DR(high) IgG+ plasma cells in the peripheral blood of patients with bullous pemphigoid: NC16a-specific cells belong to the short-lived plasma blast population. (2010) (3)
- [Simultaneous occurrence of extra-abdominal fibromatosis and post-traumatic keloid]. (1994) (3)
- Research in practice: Treatment of autoimmune bullous disorders (2009) (3)
- Status quo und Perspektiven der Hautkliniken in Deutschland: Versorgungsspektren und Personalsituation (2021) (3)
- Disease progression and response to therapy in pemphigus based on a registry (2022) (3)
- Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassays. (2020) (3)
- FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus (2022) (3)
- Clinical and Molecular Characterization of Autoimmune Bullous Diseases. (2008) (3)
- Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus (2023) (2)
- Stationäre Versorgung von Hautkrankheiten in Deutschland: Multi‐Source‐Analyse zum aktuellen und zukünftigen Bedarf (2021) (2)
- Dyshidrosiform pemphigoid induced by ustekinumab in a patient with ulcerative colitis (2022) (2)
- Empfehlungen für den Einsatz von Rituximab (anti‐CD20‐Antikörper) bei bullösen Autoimmundermatosen § (2008) (2)
- [Detecting skin cancer: paraneoplastic skin diseases]. (2020) (2)
- IgG against the membrane-proximal portion of the desmoglein 3 ectodomain induces loss of keratinocyte adhesion, a hallmark in pemphigus vulgaris. (2022) (2)
- Autoreactive CD4+ T-cell responses to the extracellular domain (ECD) of bullous pemphigoid antigen 2 (BPAG2) in BP patients (1998) (2)
- [Scaling erythemas in an infant]. (2009) (2)
- Ergebnisse einer Umfrage an deutschen Hautkliniken zur Therapie von Pemphigus und bullösem Pemphigoid (2009) (2)
- Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid (2019) (2)
- Nickel-Induced Contact Dermatitis Peripheral and Cutaneous T Cells in 17 by b Preferential Usage of TCR-V (2001) (2)
- Erratum (2010) (2)
- Lichen planus in Germany – epidemiology, treatment, and comorbidity. A retrospective claims data analysis (2022) (2)
- Long-term efficacy and safety of TNF-alpha-inhibitor infliximab in severe atopic dermatitis1 (2004) (2)
- [European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology]. (2020) (2)
- Empfehlungen für die Anwendung der Immunapherese bei der Therapie bullöser Autoimmundermatosen (2007) (1)
- Comprar Autoimmune Diseases of the Skin 3rd Edition | Michael Hertl | 9783211992241 | Springer (2010) (1)
- Schuppende Erytheme bei einem Säugling (2009) (1)
- Erfolgreiche Rituximab‐Behandlung des bullösen Pemphigoids bei Jugendlichen mit ösophagealer Vernarbung aufgrund von “epitope spreading” (2016) (1)
- Erratum to "Severity score indexes for blistering diseases" [Clin Dermatol 2011:30 108-113]. (2016) (1)
- 079 Detection and monitoring of autoreactive T cell responses against desmoglein 1 and 3 in patients with pemphigus (2019) (1)
- [Autoimmune skin diseases]. (2015) (1)
- Severe Cutaneous Adverse Drug Reactions (2020) (1)
- Wirksamkeit des IL‐17‐Hemmers SECUKINUMAB bei akuter generalisierter exanthematische Pustulose (AGEP) (2019) (1)
- Autoimmunity against Desmogleins in Pemphigus Vulgaris (2005) (1)
- Allergological diagnostics of hypersensitivity reactions to drugs (2008) (1)
- Sperm-Specific T Lymphocytes (2009) (1)
- Streifenförmige Erytheme unter Polychemotherapie (2010) (1)
- [Bullous autoimmune dermatoses. 1: Classification]. (2002) (1)
- Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris (2022) (1)
- Pemphigus vulgaris of the pompholyx type. (2010) (1)
- Pemphigus Foliaceus Autoantibodies Induce Redistribution Primarily of Extradesmosomal Desmoglein 1 in the Cell Membrane (2022) (1)
- Lepidopterismus: Erfahrungen mit dem Eichenprozessionsspinner in Marburg (2021) (1)
- Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases (2012) (1)
- The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab (2022) (1)
- Concidence of cotrimoxazole induced toxic epidermal necrolysis and chronic Q Fever in an Afghan shepherd (2022) (1)
- Corona – und kein Ende? (2021) (1)
- Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel / Allergological approach to drug hypersensitivity reactions Leitlinie der Deutschen Dermatologischen Gesellschaft (DDG) und der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) in Zusammenarbeit (2008) (1)
- Role of ADAM10 and ADAM17 in the Regulation of Keratinocyte Adhesion in Pemphigus Vulgaris (2022) (1)
- Pemphigus: a critical analysis on clinical subtypes, pathogenesis, diagnostics and established novel therapeutics (2021) (1)
- [Recognize rare diseases on the skin]. (2019) (1)
- Development of a mouse model of Pemphigus Vulgaris as a tool to evaluate nanoparticle induced antigen-specific tolerance (2019) (1)
- Extent Measures in Autoimmune Bullous Disease (2015) (1)
- Author index (2005) (0)
- Subject Index Vol. 13, 2000 (2000) (0)
- 011 Investigating the role of skin-resident T cells in pemphigus vulgaris in humans (2021) (0)
- [Paraneoplastic skin syndromes]. (2021) (0)
- Bullous Diseases: Old Blisters with New Therapeutic Targets (2015) (0)
- 038 Therapeutic efficacy of IL-17 blockade identifies lichen planus as a Th17-driven skin disorder (2017) (0)
- 033 Excision of halo nevus without PD-L1 expression may cure vitiligo (0)
- Mouse models of pemphigus: valuable tools to investigate pathomechanisms and novel therapeutic interventions (2023) (0)
- Plain language summaries in Simplified Chinese (2016) (0)
- Improving the diagnosis of autoimmune blistering dermatoses of the oral mucosa (2019) (0)
- [A severe course of bullous pemphigoid in a young man]. (2006) (0)
- 271 Oral and cutaneous lichen planus exhibit two different T cell antigenic specificities (2016) (0)
- AllelesCarriers of PV-Associated HLA Class II Pemphigus Vulgaris (PV) and Healthy Responses to Desmoglein 3 in Patients with Dichotomy of Autoreactive Th1 and Th2 Cell (2002) (0)
- Propranolol Off-Target: A New Therapeutic Option in Neutrophil-Dependent Dermatoses? (2020) (0)
- 007 Comorbidities and Complications among Pemphigus patients: a retrospective cohort study (0)
- Contents Vol. 214, 2007 (2007) (0)
- Case report: Detection of anti-bullous pemphigoid antigen 180 antibodies in a patient with Behçet’s disease (2022) (0)
- Status quo and perspectives of dermatology hospitals in Germany: spectra of health care and staff situation (2021) (0)
- [Strip-shaped erythema under polychemotherapy]. (2010) (0)
- Complete remission of prurigo pigmentosa after oral doxycycline (2022) (0)
- Photopheresis modulates TH1- and TH2- autoreactive T-cell responses to desmoglein 3 (DSG3) in patients with pemphigus vulgaris (PV) (1998) (0)
- Contents Vol. 14, 2001 (2001) (0)
- Autoreactive T cells as potential targets for immunotherapy of autoimmune bullous diseases (ABD) (1998) (0)
- Autoantibodies from PNP sera preferentially recognize desmocollins and the C-terminal epitopes of the desmoglein 3 ectodomains (2009) (0)
- 048 Dysfunctional transitional B cells in patients with pemphigus (2023) (0)
- Insektengiftallergie — Anti-IgE-Therapie (2007) (0)
- Subclinical bullous pemphigoid-detecting anti-basement membrane antibodies in elder patients with pruritic diseases (2005) (0)
- Isolation of Lymphocytes from Human Skin and Murine Tissues: A Rapid and Epitope-Preserving Approach (2022) (0)
- Sarcoidosis with concomitant hepatitis C infection treated successfully with adalimumab (2019) (0)
- 484 Lichen planus pemphigoides is a chimera of lichen planus and bullous pemphigoid (2017) (0)
- 272 Clinical response and impact on auto-reactive B cells in uncontrolled bullous pemphigoid (BP) patients treated with rituximab (2016) (0)
- [B-cell-depleting antibodies in skin diseases]. (2008) (0)
- Pemphigus Vulgaris in Healthy Individuals than in Patients with Desmoglein 3 Are More Frequently Detected Type I Regulatory T Cells Specific for (2004) (0)
- [Molecular diagnosis of collagen vascular diseases and vasculitides]. (2016) (0)
- Validation of serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita (EBA) - a multicenter analysis (2016) (0)
- 057 Detection of IgG autoantibodies against BP180 and BP230 in patients with oral lichen planus (2022) (0)
- Correction: Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris (2012) (0)
- Paraneoplastische Syndrome der Haut (2021) (0)
- Healthy Individuals in Patients with Pemphigus Vulgaris and T Cell Recognition of Desmoglein 3 Peptides (2004) (0)
- Response to ‘Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis': reply from authors (2018) (0)
- Therapy of Immunobullous Disorders (2017) (0)
- B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid (2019) (0)
- Aus der Klinik für Dermatologie und Allergologie Geschäftsführender Direktor: Prof. Dr. med. Michael Hertl des Fachbereichs Medizin der Philipps-Universität Marburg Development and validation of serological immunoassays in laminin γ-1 pemphigoid and epidermolysis bullosa acquisita Inaugural-Diss (2019) (0)
- Redox Enzymes of the Thioredoxin Family as Potential and Novel Markers in Pemphigus (2021) (0)
- [Annular erythema associated wih pruritus in a 69-year-old female]. (2005) (0)
- Targeted Therapy (2008) (0)
- BP230Clustered in Distinct Regions of BP180 and Epitopes Pemphigoid (BP) Patients Recognize Autoreactive T and B Cells from Bullous (2006) (0)
- Reviewers' list (2005) (0)
- Alleles Carriers of PV-Associated HLA Class II Pemphigus Vulgaris ( PV ) and Healthy Responses to Desmoglein 3 in Patients with Dichotomy of Autoreactive Th 1 and Th 2 Cell (2002) (0)
- Dermatomyosistis des Kindesalters (1993) (0)
- 31. Symposium Augustanum (2019) (0)
- Pemphigus: a critical review on clinical subtypes, pathogenesis, diagnostics and established and novel therapeutics. (2020) (0)
- Immuntherapie I (2011) (0)
- Different signaling patterns contribute to loss of keratinocyte cohesion dependent on autoantibody profile in pemphigus (2017) (0)
- Advances in Pemphigus and Pemphigoid (2006) (0)
- Photodynamic therapy in oral lichen planus: A prospective case-controlled pilot study (2020) (0)
- 8 Autoimmune blistering disorders (2012) (0)
- 035 CD4+ resident memory T cells colocalize with CD301b+ dendritic cells in perifollicular lymphocyte clusters in a murine delayed-type hypersensitivity model (2019) (0)
- Models of pemphigus vulgaris (2006) (0)
- Subject Index Vol. 214, 2007 (2007) (0)
- Nachruf (2019) (0)
- Deviationand Delayed Helper T Cell Immune Differential Induction of Regulatory T Cells Birch Pollen Immunotherapy Leads to (2010) (0)
- [Prof. Dr. Hans Merk on the occasion of his 65th birthday]. (2015) (0)
- Src and cortactin are involved in pemphigus skin blistering (2019) (0)
- 024 Comparative analysis of ex vivo assays aimed at identifying Desmoglein 3 reactive CD4+ T cells in pemphigus vulgaris (2021) (0)
- [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis]. (2010) (0)
- 049 Phenotypic and functional analysis of autoreactive CD4+ T cell responses against Desmoglein 3 epitopes in pemphigus vulgaris (2022) (0)
- Drug induced inhibition of lymphocyte proliferation inhibition of cyclic nucleotide phosphodiesterase or of protein kinase c (1991) (0)
- Reply to: “Dermatology's call to emergency action on climate change” (2022) (0)
- [Proceedings of the 13th congress of the German-Japanese Society of Dermatology]. (2019) (0)
- Author Correction: Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus (2023) (0)
- Catalytic antibodies in arrhythmogenic cardiomyopathy patients cleave desmoglein 2 and N-cadherin and impair cardiomyocyte cohesion (2023) (0)
- 034 Impaired frequency and function of transitional B cells in patients with pemphigus vulgaris (2022) (0)
- 035 Humanized anti-Desmoglein-3 antibodies as tools for research on the role of the neonatal Fc receptor in pemphigus vulgaris (2021) (0)
- Allelic and copy number variations in human Fc gamma receptor genes are strongly associated with susceptibility to autoimmune blistering diseases (AIBD) (2013) (0)
- Lichenoid exanthema mimicking graft-versus-host disease associated with obstructive lung disease in a non-transplanted patient. (2010) (0)
- β Preferential Usage of TCR-V (2013) (0)
- Detection of anti-desmoglein antibodies in oral lichen planus: What do we know so far (2022) (0)
- Dsg3 epitope-specific signalling in pemphigus (2023) (0)
- Regulated by HLA-DRB 1 * 04 : 02 Desmoglein 3 in Pemphigus Vulgaris Are Pathogenic IgG Antibodies against (2014) (0)
- Acknowledgement to Referees for Dermatology 2007 (2008) (0)
- S230 Diagnosis of cutaneous drug reactions: Reality and perspectives (1997) (0)
- Behandlung eines Anti‐Laminin‐γ1‐Pemphigoids mit Mycophenolatmofetil (2015) (0)
- 080 Modulation of the T helper and T follicular helper cell distribution in pemphigus patients by B cell-depleting therapy (2019) (0)
- 043 A novel tool to analyse the pathogenic impact of IgG binding to extracellular domain 5 of Desmoglein 3 (2022) (0)
- Innate immune activation as cofactor in pemphigus disease manifestation (2022) (0)
- Introduction to the Skin and Dermatology (2020) (0)
- Multifocal fixed drug eruptions caused by chlormezanone (1997) (0)
- ELISA in serological diagnosis of autoimmune bullous diseases (ABS) (1998) (0)
- 012 Pathogenic murine anti-BP230 autoantibody 20B12: Elucidating the mechanism of blister formation (0)
- 237 Impact of innate immunity on pemphigus vulgaris disease manifestation (2021) (0)
- Paraneoplastic pemphigus with anti-BP 180 autoantibodies and Castleman ' s disease Short title : Paraneoplastic pemphigus with anti-BP 180 IgG autoantibodies (2016) (0)
- Corrigendum to “Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DRβ1*0402 tetramers” [Clin. Immunol. 122 (2007) 330–337] (2012) (0)
- Contents Vol. 13, 2000 (2000) (0)
- Dermatologie Kompakt und Praxisnah ‐ die Tagung für den aktuellen und kompakten Überblick! (2020) (0)
- Retinoidstoffwechsel der menschlichen Haut und Charakterisierung der Retinoidresistenz im malignen Melanom (2017) (0)
- Biologics bei entzündlichen Hauterkrankungen (2004) (0)
- Modulation der IL-31 Serumkonzentration durch spezifische Immuntherapie bei Patienten mit IgE-vermitteltem Asthma bronchiale und allergischer Rhinitis (2014) (0)
- Register‐Studie zu Krankheitsentwicklung und Therapieansprechen bei Pemphigus (2022) (0)
- Phänotypische und funktionelle in vitro-Untersuchungen läsionaler T-Lymphozyten bei bullösen Arzneiexanthemen (1994) (0)
- Zwanzig Jahre und kein bisschen leise! (2023) (0)
- Effektivität und Sicherheit von Rituximab beim Pemphigus: Ergebnisse aus dem Deutschen Register für Autoimmunerkrankungen (2012) (0)
- XXIX. Symposium Augustanum – Jahrestagung der Deutsch‐Italienischen Gesellschaft für Dermatologie e. V. in Genua am 27. Mai 2016 (2016) (0)
- Laudatio zum 80. Geburtstag von David R. Bickers, M.D (2021) (0)
- Wir trauern um unseren früheren Präsidenten, einen international renommierten Dermatologen, Visionär, hochgeschätzten Kollegen und großartigen Menschen (2020) (0)
- Chirurgische Therapie der Gynäkomastie durch ultraschall-assistierte Fettabsaugung (UAL): Vorteile im Vergleich mit konventionellen Verfahren (2002) (0)
- Chirurgische Therapie der Gynäkomastie durch ultraschall-assistierte Fettabsaugung (UAL): Vorteile im Vergleich mit konventionellen Verfahren (2002) (0)
- Anaphylaxie auf dem Zahnarztstuhl – eine ungewöhnliche Manifestation einer Kontakturtikaria (2008) (0)
- Lichen planus in Deutschland – Epidemiologie, Behandlung und Komorbidität. Eine retrospektive Krankenkassendatenanalyse (2022) (0)
- Forschen für die Praxis: Therapie bullöser Autoimmunerkrankungen (2009) (0)
- Familientreffen in Dresden (2019) (0)
- Sarkoidose mit begleitender Hepatitis‐C‐Infektion erfolgreich mit Adalimumab behandelt (2019) (0)
- Nachruf Prof. Dr. med. Walter Krause 23.12.1939 in Halberstadt – 8.12.2019 in Gießen (2020) (0)
- FV01/01 Die Immunpathogenese der Psoriasis: von Neandertalern und Denisovans zu einer Autoimmunreaktion gegen Melanozyten (2023) (0)
- Anwendung von hochdosierten intravenösen Immunglobulinen in der Dermatologie (2009) (0)
- Allergologische Diagnostik von Überempfindlichkeitsreaktionen auf Arzneimittel Leitlinie der Deutschen Dermatologischen Gesellschaft (DDG) und der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI) in Zusammenarbeit mit dem Ärzteverband Deutscher Allergologen (ÄDA) und dem Ber (2008) (0)
- Geladene Vorträge (2004) (0)
- Charakterisierung von T-Lymphozyten als diagnostisches Mittel bei allergischen Arzneimittelreaktionen (2000) (0)
- Clinical and molecular characterization of autoimmune bullous diseases. (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Hertl?
Michael Hertl is affiliated with the following schools:
